Try our beta test site
5 studies found for:    anti-CD74
Show Display Options
Rank Status Study
1 Completed Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: hLL1
2 Completed Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Condition: Chronic Lymphocytic Lymphoma
Intervention: Biological: milatuzumab
3 Unknown  The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Milatuzumab
4 Completed
Has Results
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: milatuzumab;   Biological: veltuzumab;   Procedure: Correlative/Special Studies;   Procedure: Quantitative T-, B-, and NK cell subsets;   Procedure: Pharmacokinetics;   Procedure: Human Anti-Human Antibodies;   Biological: veltuzumab and milatuzumab
5 Unknown  Phase I Study of Milatuzumab for Graft Versus Host Disease
Conditions: GVHD (Acute or Chronic);   Acute Myeloid or Lymphoblastic Leukemia (AML or ALL);   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia (CML);   Multiple Myeloma (MM);   Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell);   Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
Intervention: Drug: milatuzumab

Study has passed its completion date and status has not been verified in more than two years.